Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Aug;124(8):3277-8.
doi: 10.1172/JCI77196. Epub 2014 Jul 18.

A "kiss" before conception: triggering ovulation with kisspeptin-54 may improve IVF

Comment

A "kiss" before conception: triggering ovulation with kisspeptin-54 may improve IVF

Steven L Young. J Clin Invest. 2014 Aug.

Abstract

A 30-year-old primigravid (G1P000) female with infertility secondary to her partner's oligospermia and her chronic anovulation presented 13 days after an oocyte retrieval for in vitro fertilization (IVF) with a positive home pregnancy test, abdominal distention, a 5-pound weight gain, nausea, shortness of breath, and reduced urinary frequency. Her IVF cycle included the usual cocktail for gonadotropin stimulation and was uncomplicated, except for excessively stimulated ovaries that led to a peak estradiol level of 6,000 pg/ml and the retrieval of 30 oocytes. Her past history was relevant only for anovulation due to polycystic ovarian syndrome (PCOS), though her preprocedure body mass index was normal at 21 kg/m2. Pelvic ultrasound revealed abundant ascites and enlarged ovaries, at 8 cm average diameter. Serum human chorionic gonadotropin (hCG) concentration was 200 mIU/ml; she was hemoconcentrated (hemoglobin 16 g/dl), with normal liver function and coagulation testing. An ultrasound guided, transvaginal paracentesis removed 4 liters of straw-colored fluid, resulting in significant short-term symptom relief.

PubMed Disclaimer

Comment on

  • Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.
    Jayasena CN, Abbara A, Comninos AN, Nijher GM, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Sridharan M, Mason AJ, Warwick J, Ashby D, Ghatei MA, Bloom SR, Carby A, Trew GH, Dhillo WS. Jayasena CN, et al. J Clin Invest. 2014 Aug;124(8):3667-77. doi: 10.1172/JCI75730. Epub 2014 Jul 18. J Clin Invest. 2014. PMID: 25036713 Free PMC article. Clinical Trial.

References

    1. Mansour R, et al. International Committee for Monitoring Assisted Reproductive Technologies world report: Assisted Reproductive Technology 2006. Hum Reprod. 2014;29(7):1536–1551. doi: 10.1093/humrep/deu084. - DOI - PubMed
    1. Practice Committee of American Society for Reproductive Medicine Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90(5 suppl):S188–S193. - PubMed
    1. Assisted Reproductive Technology (ART). ART 2011 National Summary Report. CDC Web site. http://www.cdc.gov/art/ART2011 Updated: December 1, 2013. Accessed: June 25, 2014
    1. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst. 2011;(10):CD009154. - PubMed
    1. Youssef MA, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst. 2011;(1):CD008046. - PubMed

Publication types